JonesResearch initiated coverage of iBio (IBIO) with a Buy rating and $7 price target The firm says the company’s extended half-life antibody platform is focused on obesity and metabolic indications. iBio’s is over 12 months away from clinical data, but the stock will move in sympathy with INHBE siRNA companies, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBIO: